Mainstream

Novartis Beats Q4 Top Line And Bottom Line Estimates; Initiates Fy25 Soft Outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Post Contentnvs, nvsefRead More

You might also be interested in reading Is It A Good Idea To Buy Curve Now? Here’s What This Founder Thinks.

January 31, 2025
In Mainstream